Erectile Dysfunction (ED) is defined as the inability to attain or maintain an erection sufficient enough for sexual intercourse. ED has a prevalence of about 50 % in men between the ages of 40 and 70 years and a prevalence for complete ED of 15 % in the same age group. ED also affects younger men and prevalence in this age group may be as high as 30 %. The recent increase in modifiable risk factors for ED, such as obesity and metabolic syndrome, has caused an increased prevalence of ED in recent years. In fact, predictive models show a projected 322 million cases of ED by 2025. The rise in ED incidence has been met with an increase in treatment options. Some of these treatment modalities are considered restorative therapy due to the fact that they may reverse the underlying changes that have caused the patient’s ED. The goal of many of these proposed options has been to cure or lessen symptomatology without causing unnecessary side effects. These restorative therapies include shockwave therapy , injectable platelet-rich plasma , and stem cell therapy (SCT). Although a relatively novel treatment modality, SCT holds promise as a regenerative therapy for ED. As
: Clavijo Rl, Kohn TP, Kohn JR, et al. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: A systematic review and meta-analysis. J Sex Med 2017;14:27-35.
: Wu YN, Wu CC, Sheu MT, et al. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med 2016;10:E294-E304.